![conference banner](/images/conference-banner.jpeg)
Abstract
A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Current HIV Research
Title: Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs
Volume: 9 Issue: 8
Author(s): Olaf Kutsch, Frank Wolschendorf and Vicente Planelles
Affiliation:
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Abstract: A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Export Options
About this article
Cite this article as:
Kutsch Olaf, Wolschendorf Frank and Planelles Vicente, Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998826
DOI https://dx.doi.org/10.2174/157016211798998826 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Medicinal Chemistry of 5-HT6 Receptor Ligands with a Focus on Arylsulfonyltryptamine Analogs
Current Topics in Medicinal Chemistry Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
Current Pharmaceutical Design Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry In Silico Dynamic Molecular Interaction Networks for the Discovery of New Therapeutic Targets
Current Pharmaceutical Design NMDA Receptor Pharmacology: Perspectives from Molecular Biology
Current Drug Targets Clozapine Safety, 35 Years Later
Current Drug Safety Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science An Updated Review on Therapeutic Potential and Recent Advances in Drug Delivery of Berberine: Current Status and Future Prospect
Current Pharmaceutical Biotechnology High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Neurochemical Imbalance in Epilepsy from Animal Model to Human
Current Psychopharmacology Recent Progress in Biological Activities of Indole and Indole Alkaloids
Mini-Reviews in Medicinal Chemistry Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Experimental Treatment Options in Absence Epilepsy
Current Pharmaceutical Design Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers MRI-Negative Medial Temporal Lobe Epilepsy can Benefit from Stereotactic Radiofrequency Thermocoagulation Applied to the Amygdalohippocampal Complex
Current Medical Imaging A Series of Trifluoromethylisoxazolyl- and Trifluoromethylpyrazolyl- Substituted (Hetero)aromatic Sulfonamide Carbonic Anhydrase Inhibitors: Synthesis, and Convenient Prioritization Workflow for Further <i>In Vivo</i> Studies
Medicinal Chemistry PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry